NEW YORK, Sept. 12, 2022 /PRNewswire/ -- The Recombinant Proteins Market research report provides a detailed analysis of emerging market trends, regional outlook, competitive landscape, and comprehensive analysis of different market segments. The recombinant proteins market is poised to grow by USD 633.23 million from 2021 to 2026, at a CAGR of 9.98% during the forecast period.
Technavio recombinant proteins market report has been prepared by focusing on both qualitative & quantitative aspects which cover- market trends, market drivers, Five forces analysis, challenges, key factors, Market size and forecast, Market segmentation, Geographical insights, and Competitive Landscape. View Free Sample Report of Recombinant Proteins Market in MINUTES.
Recombinant Proteins Market Vendors
Airway Therapeutics Inc.
Aviva Systems Biology Corp.
Bio Rad Laboratories Inc.
Bio Techne Corp.
BPS Bioscience Inc.
Elabscience Biotechnology Inc.
Enzo Biochem Inc.
GenScript Biotech Corp.
The recombinant proteins market will be affected by an increase in collaborations and strategic alliances by vendors. Apart from this, other market trends include Increased expenditure on R&D, Growing opportunities from emerging economies. Buy Sample Report.
Recombinant Proteins Market Split
The market analysis is done on the basis of regional distribution helping us to utilize & make performance estimations for the international market over the period from 2021-2026. The recombinant proteins market research report shed light on the foremost regions: North America, Europe, Asia, and the Rest of the World (ROW). Download Free Sample Report.
Imperative Insights on the following aspects:
What was the size of the global recombinant proteins industry by value?
What will be the size of the global recombinant proteins industry in 2026?
What factors are affecting the strength of competition in the global recombinant proteins industry?
How has the industry performed over the last five years?
What are the main segments that make up the global recombinant proteins market?
The recombinant proteins market research report presents critical information and factual data about the recombinant proteins industry, with an overall statistical study of this market based on market drivers, market limitations, and its future prospects. The widespread trends and opportunities are also taken into consideration in the recombinant proteins market study.
Myoglobin Market by Type and Geography - Forecast and Analysis 2022-2026: The myoglobin market share is expected to increase by USD 99.2 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.1%.
Human Organoids Market by End-user and Geography - Forecast and Analysis 2022-2026: The human organoids market share is expected to increase to USD 1.18 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 16.9%.
Recombinant Proteins Market Scope
Growth momentum & CAGR
Accelerate at a CAGR of 9.98%
Market growth 2022-2026
$ 633.23 million
YoY growth (%)
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 36%
Key consumer countries
US, Canada, Germany, Italy, China, and Japan
Leading companies, competitive strategies, consumer engagement scope
Abcam plc, Airway Therapeutics Inc., Amgen Inc., Aviva Systems Biology Corp., Bio Rad Laboratories Inc., Bio Techne Corp., BPS Bioscience Inc., Elabscience Biotechnology Inc., Enzo Biochem Inc., GenScript Biotech Corp., GigaGen Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, OriGene Technologies Inc., Prospec Tany Technogene Ltd., Proteintech Group Inc., Sanofi, Sino Biological Inc., and Thermo Fisher Scientific Inc.
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Browse for Technavio "Health Care" Research Reports
Table of Content:
1 Executive Summary
1.1 Market overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
4 Five Forces Analysis
4.1 Five forces summary
4.2 Bargaining power of buyers
4.3 Bargaining power of suppliers
4.4 Threat of new entrants
4.5 Threat of substitutes
4.6 Threat of rivalry
4.7 Market condition
5 Market Segmentation by Application
5.1 Market segments
5.2 Comparison by Application
5.3 Biotechnology research - Market size and forecast 2021-2026
5.4 Drug discovery and development - Market size and forecast 2021-2026
5.5 Biopharmaceutical production - Market size and forecast 2021-2026
5.6 Others - Market size and forecast 2021-2026
5.7 Market opportunity by Application
6 Customer Landscape
6.1 Customer landscape overview
7 Geographic Landscape
7.1 Geographic segmentation
7.2 Geographic comparison
7.3 North America - Market size and forecast 2021-2026
7.4 Europe - Market size and forecast 2021-2026
7.5 Asia - Market size and forecast 2021-2026
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
7.7 US - Market size and forecast 2021-2026
7.8 China - Market size and forecast 2021-2026
7.9 Germany - Market size and forecast 2021-2026
7.10 Italy - Market size and forecast 2021-2026
7.11 Japan - Market size and forecast 2021-2026
7.12 Canada - Market size and forecast 2021-2026
7.13 Market opportunity by geography
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
8.4 Market trends
9 Vendor Landscape
9.2 Vendor landscape
9.3 Landscape disruption
9.4 Industry risks
10 Vendor Analysis
10.1 Vendors covered
10.2 Market positioning of vendors
10.3 Abcam plc
10.4 Amgen Inc.
10.5 Bio Rad Laboratories Inc.
10.6 Enzo Biochem Inc.
10.7 Merck KGaA
10.8 Novartis AG
10.9 Novo Nordisk AS
10.11 Sino Biological Inc.
10.12 Thermo Fisher Scientific Inc.
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
11.3 Currency conversion rates for US$
11.4 Research methodology
11.5 List of abbreviations
investments in R and D by biotechnology firms and federal agencies: Biotechnology companies and research organizations are investing significantly in R and D activities to develop new technologies to improve the quality and standards of their products. They are investing in proteomics, drug testing, high-throughput screening, combinational chemistry, and the development of highly innovative environment-friendly biotechnology reagents. Increased R and D has led to improved healthcare access in the US, countries in Europe, as well as in emerging markets such as China and India, which drives the demand for biotechnology reagents.
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View original content to download multimedia:https://www.prnewswire.com/news-releases/recombinant-proteins-market-size-worth-usd-633-23-mn-by-2026--market-analysis-segmented-by-application-and-geography---technavio-301621761.html